Alector, LLC
953 Indiana Street
San Francisco
California
94107
United States
Tel: 415-231-5660
Website: http://alector.com/
About Alector, LLC
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
37 articles about Alector, LLC
-
Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002
5/6/2019
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INVOKE clinical study of AL002.
-
Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001
4/17/2019
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first frontotemporal dementia (FTD) patient in the Phase 1b portion of the INFRONT clinical study of AL001 after successful completion of the healthy volunteer single ascending dose escalation portion of the study.
-
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
-
Alector Announces Pricing of Initial Public Offering
2/7/2019
Alector, Inc. announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per share.
-
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
-
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
-
Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis Lavigne
11/16/2018
Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the following additions to its board as independent directors:
-
Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s Disease
11/15/2018
First Clinical Trial of a Program Designed to Address Multiple Brain Pathologies in Alzheimer’s Disease by Reversing Immune Dysfunction
-
Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia
9/19/2018
Alector today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001
-
Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontot...
8/8/2018
AL001 is a human recombinant monoclonal antibody, for the treatment of all patients with frontotemporal dementia. -
Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs
7/25/2018
First three programs to focus on Alzheimer’s disease and frontotemporal dementia
-
South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.
-
Science Exchange Announces Outsourced R&D Partnership With Alector
11/20/2017
Alector is the latest R&D company to choose to partner with Science Exchange.
-
AbbVie announced a strategic collaboration with Alector to develop and commercialize drugs for ALZ's disease and other neurodegenerative disorders.
-
Alector Announces Closing Of Series D Financing
1/7/2016
-
SF Biotech Startup Alector Forges Alzheimer's Pact With Pharma Giant Johnson & Johnson
3/10/2014
-
Alector See Alzheimer’s Beat; Series A To Fund Antibody Bid
11/1/2013